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ABSTRACT
Objective: The purpose of this study was to determine the ex vivo human placental transfer of
trovafloxacin from the maternal circulation to the fetal circulation.
Metkods: Six placentas from uncomplicated, term, vaginal or cesarean deliveries were studied
using the ex vivo isolated cotyledon perfusion chamber; 4C-antipyrine was used as a reference
compound to determine the clearance index (CI) of trovafloxacin.
Results: The CI of trovafloxacin was 0.19 0.13 at a mean trough concentration of 1.38 0.22
pg/ml and 0.16 0.10 at a mean peak concentration of 7.48 2.3 pg/ml as determined by our newly
developed high-pressure liquid chromatographic assay. Tissue concentration did not exceed mater-
nal concentration, and there was little or no accumulation when the perfusion system was closed for
1 hr.
Conclusions: Trovafloxacin crosses the placenta by simple diffusion and does not accumulate in
the media to any extent, nor does it bind to tissue or accumulate in the placenta. Infect. Dis. Obstet.
Gynecol. 8:228-229, 2000. (C) 2000 Wiley-Liss, Inc.
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rovafloxacin is a broad-spectrum antibacterial
fluronaphthyridone related to other synthetic
fluroquinolone compounds. There is a paucity of
information on the placental transfer and accumu-
lation of quinolone compounds in pregnant women
because of the category C risk. The adverse reac-
tions include possible skeletal malformations and
increased gestational time. Additional serious ad-
verse reactions in humans include potential hepatic
malfunction, tendinitis, and tendon rupture. How-
ever, in reported cases of at least 32 women who
received quinolone antibiotics in the first trimester
of pregnancy, no congenital abnormalities were re-
ported. 1,z The results of these pregnancies were 21
normal births, ectopic pregnancy, 4 spontaneous
abortions, 5 terminations, and unknown outcome.
Because little or no information is available on the
placental transfer of quinolone compounds, we
used our ex vivo human placental model to deter-
mine the placental transfer of trovafloxacin.
MATERIALS AND METHODS
Laboratory-standard powder of trovafloxacin was a
gift from Pfizer Pharmaceuticals (Groton, CT).
The placentas used in this study were collected
from term, uncomplicated, cesarean section or vagi-
nal deliveries in accordance with the guidelines de-
termined by the University of Texas Southwestern
Medical Center Institutional Review Board. The
placentas were collected in normal saline and were
taken to the laboratory, where the fetal circulation
was established within 15 min of delivery. The fe-
tal artery and vein were cannulated with 3- and
5-French catheters, respectively. The isolated
cotyledon was gently perfused with Eagle’s MEM
and observed for leaks and loss of membrane in-
tegrity. Placental cotyledons that were noted to
have fetal-to-maternal leaks were discarded. If
there were no detectable leaks, the perfused coty-
ledon and adjoining tissue were transferred to a
temperature-controlled chamber and perfused with
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drug-free media for 20 min to remove residual
blood and stabilize the perfusion pressure in the
fetal circulation. At the end of the 20-min stabili-
zation period, the fetal pressure was 35 mmHg. If
the fetal pressure exceeded 45 mmHg at a flow rate
of 4.0 ml/min, the placenta was discarded. The ma-
ternal circulation was then established at 17 ml/
min, and the complete perfusion system was stabi-
lized for an additional 30 min. At this time, 0.1
mg/liter of 14C-antipyrine in Eagle’s MEM was
added to the maternal circulation, and maternal
and fetal samples were collected to determine ma-
ternal fetal match, transport fraction, clearance, and
clearance index as previously described.3 A trans-
port fraction of >40% was representative of an ac-
ceptable maternal-fetal match.
Trovafloxacin was perfused into the isolated
cotyledon at concentrations of approximately 1.0
lag/ml and 7.0 lag/ml to represent the trough and
peak concentrations of the drug. Four milliliters of
maternal and fetal perfusates were collected every
10 min for hr with both the maternal and the fetal
circulations open, at which time both the maternal
and the fetal circulations were closed and the drug
was allowed to accumulate for hr, with samples
collected every 10 min as previously described. All
samples were frozen at 80C until analysis.
The high-pressure liquid chromatographic
(HPLC) assay of trovafloxacin consisted of all wa-
ter-associated analytical equipment, which con-
sisted of an M45 pump, 712B integrated sample
processor, and a 486 variable wavelength detector.
A 10-mm recorder (Linear, Inc., Houston, TX) was
used to determine the peak height of the standards
and samples. A phenomenex C18 bond-a-clone col-
umn was used for compound separation. Other ana-
lytical conditions consisted of a sensitivity setting
of 0.005 AU, a wavelength of 313 k, a flow rate of
2.0 ml/min, a 50 lal injection, and a mobil phase of
550 ml HzO, 450 ml methanol, and 40 lag/liter of
penta sulfonic acid, pH 4.0. Within-batch and be-
tween-batch reproducibility studies were per-
formed to validate the assay.
RESULTS
Reproducibility studies for the HPLC determina-
tion of trovafloxacin in the perfusates and tissue
samples showed 95% reproducibility with a mini-
TABLE I. Clearance index of trovafloxacin from
perfusion studies using an ex vivo human placenta
with both the maternal and fetal circulation
open (nonrecirculatory)
Concentration
(IJg/ml; n 6) Clearance index
Trough 1.38 + 0.22 0.19 + 0.13
Peak 7.48 + 2.3 0.16 + 0.10
aMean + standard deviation.
mum sensitivity of 0.1 lag/ml (data not shown). The
concentration and the clearance index of trova-
floxaci revealed that the maternal-fetal transfer
occurs by simple diffusion (Table 1). The accumu-
lation of trovafloxacin in placental tissue was 0.10 _
0.09 and 1.81 _
1.1 lag/g at the low and high con-
centrations, respectively.
DISCUSSION
Trovafloxacin and other quinolones all basically
have the same mechanisms of action.4 All quino-
lones exert their antibacterial action via inhibition
of type II topoisomerase DNA gyrase. DNA syn-
thesis and repair in the primate theoretically is un-
affected by this mechanism. Quinolones in general
are not recommended for use in pregnancy. Thus,
the only time trovafloxacin is used is when alter-
nate therapy was not adequate or when it was used
inadvertently, prior to the diagnosis of pregnancy.
Thus, these data are mainly for academic use but
do provide the clinician with information that the
drug does cross placental membranes by simple
diffusion. With what is known about the uses of
trovafloxacin in nonpregnant patients, it is unlikely
that quinolone compounds will be used in pregnant
patients.
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